Table of Contents
ISRN Psychiatry
Volume 2013, Article ID 621453, 7 pages
http://dx.doi.org/10.1155/2013/621453
Research Article

The Effect of Methylated Vitamin B Complex on Depressive and Anxiety Symptoms and Quality of Life in Adults with Depression

1Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
2Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA

Received 15 October 2012; Accepted 6 November 2012

Academic Editors: M. Innamorati and B. J. Mitterauer

Copyright © 2013 John E. Lewis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, W. T. Chiu, O. Demler, K. R. Merikangas, and E. E. Walters, “Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication,” Archives of General Psychiatry, vol. 62, no. 6, pp. 617–627, 2005. View at Google Scholar
  2. R. C. Kessler, P. Berglund, O. Demler et al., “The Epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R),” Journal of the American Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. World Health Organization, “The world health report 2004: changing history, annex table 3: burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002,” World Health Organization, Geneva, Switzerland, 2004.
  4. W. F. Stewart, J. A. Ricci, E. Chee, S. R. Hahn, and D. Morganstein, “Cost of lost productive work time among US workers with depression,” Journal of the American Medical Association, vol. 289, no. 23, pp. 3135–3144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Murray and A. Lopez, Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020, vol. 1 of Global Burden of Disease and Injury Series, Harvard School of Public Health, Harvard University Press, Cambridge, Mass, USA, 1996.
  6. E. Goode, “Antidepressants lift clouds, but lose “miracle drug” label,” New York Times, 2002.
  7. W. E. E. Meijer, E. R. Heerdink, W. A. Nolen, R. M. C. Herings, H. G. M. Leufkens, and A. C. G. Egberts, “Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants,” Archives of Internal Medicine, vol. 164, no. 21, pp. 2367–2370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Vedantam, “FDA links antidepressants, youth suicide risk,” Washington Post, A01, 2004.
  9. B. T. Walsh, S. N. Seidman, R. Sysko, and M. Gould, “Placebo response in studies of major depression: variable, substantial, and growing,” Journal of the American Medical Association, vol. 287, no. 14, pp. 1840–1847, 2002. View at Google Scholar · View at Scopus
  10. D. Bloch, Healing From Depression: 12 Weeks to a Better Mood: A Body, Mind, and Spirit Recovery Program, Ten Speed Press, Berkeley, Calif, USA, 2002.
  11. J. Levine, Y. Barak, M. Gonzalves et al., “Double-blind, controlled trial of inositol treatment of depression,” American Journal of Psychiatry, vol. 152, no. 5, pp. 792–794, 1995. View at Google Scholar · View at Scopus
  12. J. Levine, M. Gonsalves, I. Babur et al., “Inositol 6 gm daily may be effective in depression but not in schizophrenia,” Human Psychopharmacology, vol. 8, no. 1, pp. 49–53, 1993. View at Google Scholar · View at Scopus
  13. E. Ernst, “The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava,” Annals of Internal Medicine, vol. 136, no. 1, pp. 42–53, 2002. View at Google Scholar · View at Scopus
  14. K. M. Bell, L. Plon, W. E. Bunney Jr., and S. G. Potkin, “S-adenosylmethionine treatment of depression: a controlled clinical trial,” American Journal of Psychiatry, vol. 145, no. 9, pp. 1110–1114, 1988. View at Google Scholar · View at Scopus
  15. L. Barragán-Rodríguez, M. Rodríguez-Morán, and F. Guerrero-Romero, “Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial,” Magnesium Research, vol. 21, no. 4, pp. 218–223, 2008. View at Google Scholar · View at Scopus
  16. M. Folstein, T. Liu, I. Peter et al., “The homocysteine hypothesis of depression,” American Journal of Psychiatry, vol. 164, no. 6, pp. 861–867, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. T. Beck, R. A. Steer, and G. K. Brown, Manual for Beck Depression Inventory-II, Psychological Corporation, San Antonio, Tex, USA, 1996.
  18. A. T. Beck and R. A. Steer, Beck Anxiety Inventory Manual, Harcourt Brace and Company, San Antonio, Tex, USA, 1993.
  19. J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992. View at Google Scholar · View at Scopus
  20. S. N. Blair, W. L. Haskell, and P. Ho, “Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments,” American Journal of Epidemiology, vol. 122, no. 5, pp. 794–804, 1985. View at Google Scholar · View at Scopus
  21. C. B. Taylor, T. Coffey, and K. Berra, “Seven-day activity and self-report compared to a direct measure of physical activity,” American Journal of Epidemiology, vol. 120, no. 6, pp. 818–824, 1984. View at Google Scholar
  22. N. Bachinskaya, R. Hoerr, and R. Ihl, “Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial,” Neuropsychiatric Disease and Treatment, vol. 7, no. 1, pp. 209–215, 2011. View at Publisher · View at Google Scholar
  23. S. Yancheva, R. Ihl, G. Nikolova, P. Panayotov, S. Schlaefke, and R. Hoerr, “Ginkgo biloba extract EGb 761, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial,” Aging and Mental Health, vol. 13, no. 2, pp. 183–190, 2009. View at Publisher · View at Google Scholar · View at Scopus